<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/665E3D2C-C21E-44A7-A346-AB2C948142F9"><gtr:id>665E3D2C-C21E-44A7-A346-AB2C948142F9</gtr:id><gtr:firstName>Niloufar</gtr:firstName><gtr:surname>Safinia</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002000"><gtr:id>A1391C50-548E-4CB1-9F2A-FD7368EC30B9</gtr:id><gtr:title>Human Tregs with 'direct' allospecificity can prevent rejection of human hepatocytes in a humanised mouse model.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002000</gtr:grantReference><gtr:abstractText>Liver transplantation is a successful treatment for patients with severe liver disease. Despite this, the majority of patients are maintained on immunosuppressants (IS) life long with associated side effects, affecting long term outcome. The goal of this study is, therefore, to devise protocols to enable the patient to accept their graft without the need for long term use of IS. Interestingly, populations of immune cells in the recipient, called regulatory T cells, have been shown to regulate the patient?s immune system and prevent against organ rejection. The aim of our research is to develop new treatments that involve increasing the number of these cells in the recipient. We will a. isolate these cells from the recipient, expand them and ensure they are stable in culture. b. we will ensure they have a ?specific? inhibitory role on the immune system i.e. they prevent liver rejection, but do not cause general/total immunosuppression c. We will use animal models of liver transplantation to show the safety and efficacy of these cells before re-introduction into the patient. This work will pave the way towards the development of protocols to induce tolerance, leading to more individualized treatment and minimize the complications of long term immunosuppression.</gtr:abstractText><gtr:technicalSummary>Liver transplantation (LT) is a successful treatment for end-stage liver disease. Despite this, long-term survival remains suboptimal because of the morbidity and mortality associated with long term use of immunosuppression (IS). There is, therefore, a pressing need to devise protocols that induce a sustained state of ?specific? tolerance to donor liver alloantigens in order to minimise or completely withdraw IS. 
CD4+CD25+FOXP3+T cells (Tregs) play an important role in the induction and maintenance of immune tolerance and promote transplantation tolerance in animal models. Clinical protocols, using ?polyclonal? Tregs has been shown to inhibit graft versus host disease (GvHD) after haematopoietic stem cell transplantation. Based on our prior work with mouse Tregs we hypothesise that the use of donor alloantigen-specific Tregs will confer the additional advantage that their immunomodulatory function would be concentrated at the site of the transplant with avoidance of pan-suppression.
Of importance, alloantigens can be recognised by T cells either as intact HLA molecules presented by donor-derived antigen presenting cells (APCs) (?direct? pathway) or after processing of allogeneic HLA molecules to produce allopeptides that can be presented by recipient HLA molecules expressed by recipient APCs (?indirect? pathway). We aim to generate Tregs with ?direct? allospecificity to promote the induction of ?specific? tolerance characterised by prevention of rejection in a humanised mouse model of hepatocyte transplantation. We will address this in three ways:
 First, polyclonal Tregs will be isolated and expanded from peripheral blood of healthy volunteers. Rapamycin and all-trans retinoic acid will be used to promote the stability of these cells in vitro and to optimise the expression of CXCR3, a chemokine receptor involved in T cell migration to the liver.
 Second, Tregs with ?direct? allospecificity will be generated by co-culturing Tregs witendritic cells vs B cells); alloactivate Tregs will then be enriched by bead separation after addition of antibodies specific for activation antigens and expanded. The antigen specific suppressive function of these cells will be evaluated.
Third, a humanised mouse model of hepatocyte transplantation will be used to assess the migratory ability, suppressive function and stability of antigen specific Tregs in vivo.
This research program will address the current challenges facing LT, namely the shortage of donor organs and the complications of IS. It focuses on the therapeutic application of Tregs in the context of LT. The clinical translation of this work will lead to the generation of tolerance promoting protocols used to increase the pool of ?operationally? tolerant LT recipients.</gtr:technicalSummary><gtr:fund><gtr:end>2014-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-05-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>237276</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences KCL</gtr:department><gtr:description>Regulatory T cell dysfunction in Alcohol Related Cirrhosis; a critical role of heme-oxygenase 1</gtr:description><gtr:id>A7EA7417-6036-49B7-9B82-CC2AF1349D2F</gtr:id><gtr:impact>Manuscript being written and key experiments completed</gtr:impact><gtr:outcomeId>5464ab304d4fa0.37499356-1</gtr:outcomeId><gtr:partnerContribution>Planning of key experiments, sharing of knowledge, reagents.</gtr:partnerContribution><gtr:piContribution>Professor Giovanni Mann has expertise in HO-1.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Francisco</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with Dr Tang Qizhi (Prof Bluestone Laboratoty , UCFS)</gtr:description><gtr:id>DE0ACDD1-F738-4261-B1A4-2D0DFDAD599D</gtr:id><gtr:impact>We are soon submitting a paper to blood</gtr:impact><gtr:outcomeId>TJhgAXXdAZL-1</gtr:outcomeId><gtr:partnerContribution>I carried out all the in vivo experiments for this collaboration which was set to test the function of alloantigen specific Tregs</gtr:partnerContribution><gtr:piContribution>exchange and sharing of protocols, of samples and sharing of ideas</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Two abstracts accepted for oral presentation at the British Transplant Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>541EE55C-C241-460B-998A-C7B5F0157745</gtr:id><gtr:impact>Both presentations were made to consultants and academics who has attended the 2013 British Transplant society meeting in Bournemouth. 
presentation 1;
'Isolation and expansion of regulatory T cells from liver transplant recipients at GMP standards; Implications for Cell Therapy Application'

Presentation 2;
'Alloantigen specific human regulatory T cells stimulated with CD40L activated allogeneic B cells prevents allograft damage in a humanised mouse model'.

The meeting and the presentation of the work fostered collaborations between groups</gtr:impact><gtr:outcomeId>Yrab9kWoyUF</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>science museum event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>51CA5BC5-FB21-4E82-BB52-C9CD2B40EE69</gtr:id><gtr:impact>The event held at the science museum was entitled 'The science and art of transplantation; a pop-up exhibition. This involved designing an activity aimed at the general public of all ages demonstrating the rationale behind adoptive cell therapy in the setting of solid organ transplantation.

The exhibition raised awareness on cell therapy and aroused great interest on the clinical trial soon to start at KCL (ThRIL, Treg immunotherapy in the context of liver transplantation).</gtr:impact><gtr:outcomeId>ojzwtQwSNtU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2042677</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS DCS scheme</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K025538/1</gtr:fundingRef><gtr:id>3C97BDB3-988B-4556-8F2B-D32EAFAAD666</gtr:id><gtr:outcomeId>Dbguj5WcALC</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR/BRC Bridging Fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>EE849A8B-848A-42FA-B91D-1BC0E399BCE2</gtr:id><gtr:outcomeId>5464ac1fbbd441.24085891</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The DCS/DPFS scheme recently supported the trial of Treg immunotherapy in the context of liver transplantation. The trial soon to commence at KCL (ThRIL) is a phase I dose escalation study, assessing the safety and tolerability of these cells in the context of liver transplantation (with determination of the maximum tolerated dose).</gtr:description><gtr:id>4060A111-95D8-4920-97A1-D2D3DD11471B</gtr:id><gtr:impact>The rationale for Treg immunotherapy is the induction of immune tolerance. A state in which the recipient can accept the allograft without the need to be on immunosuppression. With Treg immunotherapy we aim to improve the quality of life of the transplant recipient and decrease the side effects associated with the long term use of immunosuppressants.</gtr:impact><gtr:outcomeId>drX2NheU5ew</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Regulatory T cell Immunotherapy</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4C031C81-CA07-4DE2-81C0-90D8418C00EA</gtr:id><gtr:title>An Alliance with miltenyi biotec in the fight for tolerance: A venture into no man's land. MACS &amp;amp; more Anniversary Edition 2014</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5464a9d7eebec5.02324829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FD2D58E-3D42-486A-8213-67AC4816E264</gtr:id><gtr:title>Regulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in Transplantation.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>58c9214cd64259.09853038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11C54AFB-B5BD-4AB0-BEA9-7B8E78A913C0</gtr:id><gtr:title>A role for gut-associated lymphoid tissue in shaping the human B cell repertoire.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_15343_23_23940259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>397FE375-8252-4A01-B040-407796B9A023</gtr:id><gtr:title>Regulatory T cells: tolerance induction in solid organ transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e40ea6a39fae2baf5393f722dd9d371"><gtr:id>3e40ea6a39fae2baf5393f722dd9d371</gtr:id><gtr:otherNames>Vaikunthanathan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5aa84287569219.14775244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D45B9A42-1178-496A-922C-DB40B37EF196</gtr:id><gtr:title>Microbiota, immunity and the liver.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e40ea6a39fae2baf5393f722dd9d371"><gtr:id>3e40ea6a39fae2baf5393f722dd9d371</gtr:id><gtr:otherNames>Vaikunthanathan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>5aa84287838345.96078551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13CD1A37-73CF-4CA2-9C98-602043701335</gtr:id><gtr:title>Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bb453a9737fc82f8737f2fba61ff2cc"><gtr:id>2bb453a9737fc82f8737f2fba61ff2cc</gtr:id><gtr:otherNames>Putnam AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_15343_23_24102808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AEC8C61-9E9F-44C2-AA8C-59D1164F0CE5</gtr:id><gtr:title>Promoting transplantation tolerance; adoptive regulatory T cell therapy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>pm_15343_23_23574313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E52B8EE2-2EDC-4313-958A-44054DFF5043</gtr:id><gtr:title>Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c9214d174729.57503497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A60CBC09-8058-41AB-AB57-11E91CB4476E</gtr:id><gtr:title>T-cell alloimmunity and chronic allograft dysfunction.</gtr:title><gtr:parentPublicationTitle>Kidney international. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0098-6577</gtr:issn><gtr:outcomeId>pm_15343_23_21116312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>630CC773-8300-4455-8941-1521D452D2A7</gtr:id><gtr:title>Humanized Mice as Preclinical Models in Transplantation.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>58c9214d45d4e8.60699021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A866E4F-63A8-4F52-89E1-636ADAFCA469</gtr:id><gtr:title>Adoptive regulatory T cell therapy: challenges in clinical transplantation.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>pm_15343_23_20616725</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002000</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>